Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials

Traditionally, the major objective in phase I trials is to iden- tify a working-dose for subsequent studies, whereas the major endpoint in phase II and III trials is treatment efficacy. The dose sought is typ- ically referred to as the maximum tolerated dose (MTD). Several sta- tistical methodologies have been proposed to select the MTD in cancer phase I trials. In this manuscript, we focus on a Bayesian adaptive design, known as escalation with overdose control (EWOC). Several aspects of this design are discussed, including large sample properties of the sequence of doses selected in the trial, choice of prior distri- butions, and use of covariates. The methodology is exemplified with real-life examples of cancer phase I trials. In particular, we show in the recently completed ABR-217620 (naptumomab estafenatox) trial that omitting an important predictor of toxicity when dose assignments to cancer patients are determined results in a high percent of patients experiencing severe side effects and a significant proportion treated at sub-optimal doses.

[1]  Naitee Ting.  Dose Finding in Drug Development , 2006 .

[2]  Mourad Tighiouart,et al.  EWOC 2.0: Interactive Software for Dose Escalation in Cancer Phase I Clinical Trials , 2007 .

[3]  C. Adcock.  Sample size determination : a review , 1997 .

[4]  D. Faries,et al.  Practical modifications of the continual reassessment method for phase I cancer clinical trials. , 1994, Journal of biopharmaceutical statistics.

[5]  J. O'Quigley.  Sequential design and analysis of dose finding studies in patients with life threatening disease , 1990, Fundamental & clinical pharmacology.

[6]  高橋 聡,et al.  Common Terminology Criteria for Adverse Events (CTCAE) v3.0による胃癌術後合併症の解析 , 2006 .

[7]  J B Greenhouse,et al.  Bayesian methods for phase I clinical trials. , 1992, Statistics in medicine.

[8]  S. Zacks,et al.  Bayes sequential search of an optimal dosage: linear regression with both parameters unknown , 1981 .

[9]  André Rogatko,et al.  Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W J Shih,et al.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. , 2001, Biostatistics.

[11]  D. Anbar,et al.  Stochastic approximation methods and their use in bioassay and phase i clinical trials , 1984 .

[12]  S. Piantadosi,et al.  Practical implementation of a modified continual reassessment method for dose-finding trials , 1998, Cancer Chemotherapy and Pharmacology.

[13]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[14]  Seiichiro Yamamoto,et al.  Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.

[15]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[16]  Weichung Joe Shih,et al.  Unifying CRM and EWOC designs for phase I cancer clinical trials , 2009 .

[17]  Elkan F Halpern,et al.  Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. , 2004, JAMA.

[18]  S. Chevret,et al.  Statistical methods for dose-finding experiments , 2006 .

[19]  J. Koziol,et al.  Phase I cancer trials: limitations and implications. , 1992, Molecular biotherapy.

[20]  Ying Kuen Cheung,et al.  Coherence principles in dose-finding studies , 2005 .

[21]  Mourad Tighiouart,et al.  New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I , 2005, Clinical Cancer Research.

[22]  M. Tighiouart,et al.  Dose Finding in Oncology—Parametric Methods , 2006 .

[23]  T. Braun,et al.  Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM. , 2003, Controlled clinical trials.

[24]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[25]  Sarah Zohar,et al.  Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules , 2003, Comput. Methods Programs Biomed..

[26]  S. Møller,et al.  An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.

[27]  Andrew Thomas,et al.  WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..

[28]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[29]  N. Saijo,et al.  Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. , 1999, International journal of oncology.

[30]  M. Tighiouart,et al.  Dose‐Escalation with Overdose Control , 2006 .

[31]  S Zohar,et al.  The continual reassessment method: comparison of Bayesian stopping rules for dose‐ranging studies , 2001, Statistics in medicine.

[32]  J. Whitehead,et al.  Bayesian decision procedures with application to dose-finding studies , 1997 .

[33]  J. Babb,et al.  Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control , 2005, Statistics in medicine.

[34]  Shelemyahu Zacks,et al.  Optimal Bayesian-feasible dose escalation for cancer phase I trials , 1998 .

[35]  William F Rosenberger,et al.  Competing designs for phase I clinical trials: a review , 2002, Statistics in medicine.

[36]  G. Hudes,et al.  Patient Characteristics Compete with Dose as Predictors of Acute Treatment Toxicity in Early Phase Clinical Trials , 2004, Clinical Cancer Research.

[37]  J O'Quigley,et al.  Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.

[38]  Anastasia Ivanova,et al.  Escalation, group and A + B designs for dose‐finding trials , 2006, Statistics in medicine.

[39]  C. F. Wu,et al.  Efficient Sequential Designs with Binary Data , 1985 .

[40]  Elizabeth Garrett-Mayer,et al.  The continual reassessment method for dose-finding studies: a tutorial , 2006, Clinical trials.

[41]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[42]  A Rogatko,et al.  Patient specific dosing in a cancer phase I clinical trial , 2001, Statistics in medicine.

[43]  D.,et al.  Regression Models and Life-Tables , 2022 .

[44]  B E Storer,et al.  An evaluation of phase I clinical trial designs in the continuous dose–response setting , 2001, Statistics in medicine.

[45]  B. Vidakovic,et al.  Patient-Specific Dose Adjustment in the Cancer Clinical Trial Setting , 2008, Pharmaceutical Medicine.

[46]  I. Ray-Coquard,et al.  Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.